I don’t prescribe. I’m a counsellor, so medication is not my lane — and yet it’s the single most common thing adults raise in the first ten minutes of an ADHD appointment. Not “teach me a system.” Not “help me with my emotions.” It’s: am I on the right one, is this the right dose, and why does everyone else seem to have figured this out?
Here’s the pattern I notice more than any other. When someone tells me their medication “isn’t working,” roughly half the time the medication is doing exactly what medication does — and what’s actually broken is something the medication was never going to touch. Sleep debt from a two-week rotation at the mine. An 11-hour workday against an 8-hour formulation. Untreated anxiety that looks like inattention. A dose that was set three years ago at a walk-in and never revisited because nobody scheduled a follow-up.
The other half of the time? The medication genuinely isn’t right, the person knows it, and they’ve been sitting on that for eighteen months because they didn’t know what to say to their doctor.
This article is about both halves. It won’t tell you what to take. It will tell you what the categories are, what “working” is actually supposed to look like, why it stops looking like that, and — the part I care about most — the specific sentences that make a seven-minute appointment with your prescriber useful instead of frustrating.
TL;DR
- ADHD medications in Canada fall into two broad groups: stimulants (methylphenidate-type and amphetamine-type) and non-stimulants (atomoxetine, guanfacine, and some off-label options).
- The two stimulant classes are not interchangeable. Failing one says very little about the other. This is the single most useful thing most people don’t know.
- “Working” is not “I feel focused.” It’s a change in what you can actually start, finish, and follow through on across a normal day.
- Side effects are common early, often settle, and are worth reporting rather than tolerating in silence — especially anything cardiovascular.
- Medication does not teach skills. It changes the conditions under which skills can be learned. If nobody is doing the second part, the first part will plateau.
But here’s what most people miss
A stimulant trial that “failed” often failed on duration, not on molecule. Someone takes an 8-hour formulation, does fine until 2 p.m., falls apart by 4 p.m., and concludes the drug doesn’t work. That’s not a non-response. That’s a coverage mismatch — and it’s a completely different conversation with a prescriber.
“Tolerance” is frequently a life change in disguise. I see this constantly. The medication didn’t stop working in March; a promotion, a new baby, night shifts, or a mental health flare raised the demand load past what the same dose could carry. Same dose, harder job.
The most under-asked question in Saskatchewan isn’t about the drug — it’s about the follow-up. Adults get titrated once and then go years without a review. Guidelines describe ADHD as a chronic condition needing ongoing individualized monitoring, but in practice, outside Saskatoon and Regina, “ongoing monitoring” often means an annual renewal fax. If nobody schedules the check-in, it doesn’t happen.
Scope, and what I can and can’t do here
I’m a Canadian Certified Counsellor. I cannot diagnose ADHD, prescribe medication, or tell you whether a specific drug or dose is right for you. Diagnosis and prescribing come from a physician, nurse practitioner, psychiatrist, or registered psychologist depending on the question. At STG Health, when medical clarification is part of the picture, that comes from our nurse practitioner — not from me.
What I can do is what I do every week: help people understand the landscape, notice when something isn’t adding up, and walk into their next medical appointment with a clear, specific, well-organized question instead of a vague sense that something’s off. That’s the job here.
This article is written for adults in Saskatchewan, which shapes a few things: what’s actually on the provincial formulary, what shift work does to a medication schedule, and how long it takes to see a prescriber in a northern or rural community versus a city.
What are the actual types of ADHD medication available in Canada?
Two groups. Stimulants and non-stimulants.
Stimulants split into two chemically distinct families:
- Methylphenidate-type — the Ritalin family. Immediate-release, sustained-release, and several long-acting formulations that release medication over different curves across the day.
- Amphetamine-type — the dextroamphetamine, mixed amphetamine salts, and lisdexamfetamine group. Also available in short and long-acting forms.
They feel similar on paper and behave differently in people. This matters enormously, and I’ll come back to it.
Non-stimulants in Canada are a shorter list than the internet suggests:
- Atomoxetine — a norepinephrine reuptake inhibitor, Health Canada–indicated for children six and over, adolescents, and adults. Not a controlled substance. Works gradually rather than dose-by-dose.
- Guanfacine extended-release — an alpha-2 agonist, Health Canada–approved for ages 6 to 17 only, both on its own and alongside a stimulant. Adult use exists but is off-label, which is a conversation your prescriber needs to walk you through.
- Bupropion — an antidepressant used off-label for ADHD in some adults, particularly where mood or nicotine use is also in the picture. Modest evidence, real place in the toolkit.
One clarification worth making because it comes up in almost every session where someone has been reading American forums: viloxazine (Qelbree) is not available in Canada. It’s approved in the United States for children and adults. A Canadian submission to Health Canada was filed and then withdrawn in early 2026 for manufacturing reasons, with a resubmission expected at some later point. If you read about it on a US site, it is not something your Saskatchewan prescriber can write for you today.
A short note on what the evidence actually says: the largest comparison of ADHD medications to date pooled 133 trials, including more than 10,000 adults, and concluded that for adults, amphetamine-type stimulants are generally the strongest short-term first choice, with methylphenidate, bupropion, and atomoxetine also clearly outperforming placebo. That’s a population-level statement, not a personal one. Population averages tell you where to start. They tell you nothing about you specifically — which brings us to the most useful fact in this entire article.
The class-switch fact nobody tells you
In double-blind trials using a single stimulant, roughly 25 to 35 percent of participants are classified as non-responders. That number gets quoted a lot, usually as evidence that ADHD medication is overhyped.
But look at the crossover studies — the ones where people who failed one stimulant class were then trialled on the other. Across those studies, somewhere between 68 and 97 percent responded to at least one of the two classes, while only a subset responded to both.
Read that again, because it changes what “the medication didn’t work for me” means. If you tried a methylphenidate product, felt nothing or felt awful, and stopped — you have tested one of two doors. Many people who are convinced they’re “medication non-responders” have never tried the other class at all.
I’ve had clients carry that conclusion for a decade. One trial, one bad reaction, a permanent self-label. It’s one of the most consequential and most correctable misunderstandings I encounter.
How do you know if ADHD medication is actually working?
The honest answer: not by how you feel, and definitely not by whether you feel “focused.”
Medication effects are frequently unremarkable from the inside. People expect a switch to flip. What they usually get is a quiet absence of friction — you sit down and the thing starts, without the twenty-minute wrestling match that used to precede it. That’s easy to miss, and easy to dismiss as “I guess I was just having a good day.”
So look at behaviour, not sensation. Over a normal week, has anything changed in:
- Initiation — the gap between deciding to do something and beginning it
- Completion — whether started things reach an end
- Switching — how badly it costs you to be interrupted and return
- Follow-through on the boring stuff — the tax slip, the form, the callback
- Emotional recovery time — how long a small frustration hijacks the rest of your day
That last one is underrated. For a lot of adults, the clearest medication effect isn’t attentional at all. It’s that the sting of a critical email lasts twenty minutes instead of consuming the entire evening. If you deal with that pattern intensely, our article on whether rejection sensitive dysphoria is what you actually have unpacks what’s underneath it and what responds to what.
A practical suggestion, and it costs nothing: track three things daily for two weeks — time you took the dose, one function you care about rated 0 to 10, and any side effect. Two weeks of that is worth more to a prescriber than an hour of you trying to describe a fuzzy impression. It’s also the single most effective thing I’ve seen turn a rushed appointment into a productive one.
Why ADHD medication stops working — or seems to
Nine times out of ten, when someone tells me the medication quit on them, it’s one of these. Roughly in order of how often I see it:
The duration doesn’t match your day. A formulation covering eight hours against a twelve-hour workday isn’t failing. It’s finishing. The 4 p.m. collapse, the impossible drive home, the evening where nothing gets done — that’s the coverage window closing, and it’s addressable.
Sleep. This is the big one in Saskatchewan, and it deserves its own paragraph. Two nights of poor sleep will erase the perceived benefit of a well-chosen medication. For anyone on rotation at a potash or uranium site, on nights in health care, or long-haul on the highway, the medication is being asked to compensate for a sleep deficit it cannot touch. I see people escalate doses chasing an effect that a fixed sleep schedule would have restored for free. If this is you, our ADHD and sleep programming addresses the part the prescription can’t.
Something else is also going on. Canadian guidelines note that around 85 percent of adults with ADHD have at least one co-occurring condition. Anxiety, depression, trauma responses, and substance use all produce concentration problems. If untreated depression is doing the work, no stimulant dose will fix it — and increasing the dose to try usually just adds side effects.
Timing and food. Some formulations behave differently with or without a meal, or with acidic drinks. Small variable, occasionally a large effect.
Life demand went up. The dose is the same. The job is harder. The kid is newer. This is not tolerance and it should not be treated as failure.
Actual tolerance. It exists. It’s less common than people assume, and it’s a legitimate reason to review with your prescriber — but it should be the conclusion after the other five have been ruled out, not the first assumption.
Notice how many of those are not medication problems. That’s not an argument against medication. It’s an argument for knowing which problem you’re actually solving before you change the prescription.
Side effects: what’s common, what settles, and what warrants a call
Most side effects show up in the first one to two weeks and diminish. Some don’t. A few need attention right away.
| Effect | Typical pattern | Worth mentioning at your next visit? |
|---|---|---|
| Reduced appetite | Common early, often eases | Yes — especially if meals are being skipped |
| Trouble falling asleep | Common; often timing-related | Yes — dose timing is frequently adjustable |
| Dry mouth, headache | Common early, usually settles | If persistent beyond a few weeks |
| Feeling flat, blunted, “not myself” | Not something to endure | Yes — this often signals dose or fit |
| Irritability as the dose wears off | Fairly common | Yes — the wear-off curve can be addressed |
| Raised heart rate or blood pressure | Monitored routinely | Yes — should be checked, not guessed at |
| Chest pain, fainting, severe shortness of breath | Not expected | Contact a medical provider promptly |
| New or worsening thoughts of self-harm | Not expected | Contact a medical provider promptly. 988 or 811 are available now |
On the cardiovascular question, because people ask and deserve a straight answer rather than reassurance or alarm.
A large Swedish study published in JAMA Psychiatry in 2024 followed 278,027 people aged 6 to 64 and found that longer cumulative use of ADHD medication was associated with increased odds of cardiovascular disease — about a 4 percent increase in odds per additional year of use, driven mainly by hypertension, with people using medication more than five years showing roughly 23 percent higher odds than non-users.
Three things to hold alongside that. It’s observational, so it demonstrates association rather than causation. The absolute risk for most individuals remains low. And it doesn’t say “stop” — it says blood pressure monitoring is a genuine part of long-term ADHD care rather than a formality. If nobody has checked your blood pressure since you started, that’s a reasonable thing to raise.
Guanfacine has its own cardiac considerations — in trials with 6-to-17-year-olds it produced a small average increase in the QTc interval — which is one of several reasons its adult use is a prescriber-level conversation rather than a website-level one.
The dose question: why “more” is usually the wrong instinct
Titration is not a ladder you climb until you reach the top. It’s a search for the point where function improves and side effects stay acceptable — and for some people that point is well below the maximum, and for a few it’s well above where their prescriber started.
Two things worth understanding:
Dose isn’t proportional to body size or symptom severity. It’s individual. Someone twice your weight may need less. This is why the process involves adjustment and follow-up rather than a formula.
Going higher past the right point makes things worse, not better. Overshooting typically produces the flat, wired, joyless state people describe as “I don’t feel like myself.” That’s not proof you need more. It’s usually proof you passed the window.
The uncomfortable reality I run into a lot: many adults were titrated once, at initiation, and never reviewed. Guidelines describe frequent follow-up until stabilization and then ongoing individualized monitoring. If your last medication conversation was in 2022 and consisted of a renewal, you have not been monitored — you have been renewed. Those are different things, and you’re allowed to ask for the first one.
What to actually ask your prescriber
This is the part I’d print out.
Prescriber appointments are short. Preparation converts a vague complaint into an actionable clinical question. Pick the two or three that fit your situation — not all of them.
If you’re just starting
- Which class is this, methylphenidate or amphetamine?
- How many hours of coverage should I expect, and when should I take it relative to my actual day?
- What should improve if this is working, and by when?
- What side effects should I expect early versus report immediately?
- When is my follow-up, and what should I bring to it?
If it works, then stops mid-day
- Is this a duration issue rather than a dose issue?
- Is there a longer-acting formulation, or a booster arrangement, appropriate here?
- What are we seeing at the wear-off point, and can that be smoothed?
If it never worked, or you felt terrible
- Which class did I try — and have I ever tried the other one? (The single highest-value question on this list.)
- Was the dose optimized before we concluded it failed, or did we stop at the starting dose?
- Given how I responded, is a non-stimulant worth considering?
If it “used to work”
- Has my sleep, workload, or mental health changed enough to explain this?
- Should we check for something co-occurring before adjusting the dose?
- Is this tolerance, or is this a demand change?
If you’re worried about long-term safety
- When was my blood pressure and heart rate last checked on this medication?
- Given my personal and family history, what should we monitor and how often?
- What’s the plan if my blood pressure trends up?
If cost is the barrier
- Is what I’m on covered under the Saskatchewan Drug Plan, or does it need Exception Drug Status?
- If EDS is needed, can your office submit it? (Patients cannot submit EDS requests themselves — it has to come from a prescriber, their clinic, or a pharmacy.)
- Is there a covered alternative in the same class we should try first?
If you’re wondering whether to be on it at all
- What are we treating, specifically, and how will we know it’s working?
- What does the rest of the treatment plan look like — is medication the whole plan or part of one?
- What would a planned trial off medication involve, and when would that be reasonable?
Saskatchewan-specific realities worth knowing
Coverage. Saskatchewan runs an Exception Drug Status program, meaning certain medications are only covered when specific clinical criteria are documented — commonly that a listed alternative was tried first. Several long-acting ADHD products sit in this category rather than being open benefits. Requests must be submitted by a prescriber, clinic, or pharmacy; you can’t file one yourself. The provincial formulary is publicly searchable, and your pharmacist can usually tell you the status of a specific product in about a minute. If NIHB, Métis Nation, or private insurance is part of your picture, our coverage and funding page sets out what applies where.
Distance and follow-up. In La Ronge, Creighton, or anywhere north, “come back in two weeks for a titration check” is a different proposition than it is in Regina. This is precisely where prepared self-tracking earns its keep — a two-week log emailed ahead of a phone appointment can accomplish what an in-person visit would have.
Shift work. Rotating schedules break the assumption every medication schedule is built on: a stable wake time. If you’re on a two-and-two rotation, your medication timing question is not the same question a nine-to-five office worker is asking, and it deserves to be raised explicitly rather than left to be figured out on your own.
Wait times. If you’re still working toward diagnostic clarity rather than adjusting an existing prescription, our assessment pathway explains what’s involved and how the nurse practitioner’s role fits alongside psychometric evaluation.
Where therapy actually fits — and where it doesn’t
I’ll be direct about my own lane, including its limits.
Medication changes the conditions. It does not install skills. If attention improves but the calendar is still empty, the emails still unanswered, and the household still running on crisis mode — that’s the predictable result of treating the neurochemistry and nothing else. It’s also, in my experience, the most common reason people conclude their medication “isn’t working well enough” when the medication is doing its part.
The reverse is also true, and I’d rather say it than protect my own service line: for some adults, skills work alone has a low ceiling. Asking someone to build habits while the underlying regulation problem is untreated can be a slow, demoralizing process. Sometimes the honest recommendation is to sort out the medical side first, then come back to the behavioural work.
Where the two actually meet:
- Working out which stage of a task you stall at, so that structure targets the real failure point rather than a generic one — the framework in our task stall-point article is designed for exactly this
- Emotional regulation, which medication improves partially and unevenly, and which responds well to targeted individual work
- Sleep, which is medication’s biggest silent confounder
- Preparation for medical appointments — a surprisingly large part of what we do together
If medical input is what’s missing, our medication support pathway explains how our nurse practitioner works alongside therapy, including what bridge prescribing does and doesn’t cover.
Frequently asked questions
Can a counsellor tell me if I’m on the right ADHD medication? No. A counsellor cannot diagnose or prescribe. What a counsellor can do is help you track function, identify what changed, and organize a clear question for your prescriber. At STG Health, medical assessment and medication consultation come from our nurse practitioner.
How long does it take to know if ADHD medication is working? Stimulants act quickly — often within an hour or two of the first dose — so early signals appear fast, though finding the right dose usually takes several weeks of adjustment. Non-stimulants like atomoxetine build more gradually, often over several weeks before a fair judgment is possible.
I tried a stimulant and it didn’t help. Does that mean medication won’t work for me? Not necessarily. The two stimulant classes are chemically distinct, and crossover research suggests most people who don’t respond to one class respond to the other. Trying one product is not the same as testing whether stimulants work for you.
Is it normal for ADHD medication to stop working? A drop in benefit is common and usually has an explanation other than tolerance — a change in workload, disrupted sleep, an untreated co-occurring condition, or a coverage duration that no longer matches your day. Genuine tolerance exists but is generally considered after other explanations are examined.
Are ADHD medications dangerous for my heart? Long-term observational research has linked cumulative ADHD medication use with modestly increased odds of cardiovascular problems, mainly hypertension. Absolute risk is low for most people and the research shows association rather than causation, but it does support routine blood pressure and heart rate monitoring as part of ongoing care. Discuss your personal and family history with your prescriber.
Is Qelbree (viloxazine) available in Canada? No. It is approved in the United States, but the Canadian regulatory submission was withdrawn in early 2026 for manufacturing reasons, with resubmission anticipated at a later date. It cannot currently be prescribed in Canada.
Does the Saskatchewan Drug Plan cover ADHD medication? Some products are open benefits and others require Exception Drug Status, which involves documented clinical criteria. EDS requests must be submitted by a prescriber, clinic, or pharmacy — patients cannot submit them directly. Your pharmacist can check the current status of a specific product.
Do I need medication to be treated for ADHD? No. Medication is one option among several, and treatment plans are individual. Many adults use psychotherapy, skills training, sleep treatment, and environmental changes with or without medication.
